$23.99
Quantity | 3 - 5 | 6 - 10 | 11 - 50 |
Price | $22.07 | $21.59 | $21.11 |
Gynakot Tablet regulates female hormones and prepares the uterus ideal for reproduction. It is a proprietary Ayurvedic medicine manufactured by Arya Vaidya Sala, Kottakkal. It is a unique herbal combination that promotes effective female reproductive system for fertility. The formulation has its basis of Sukumara Ghritam described in Astangahridayam.
Uses of Gynakot Tablet:
It supports overall systemic health and functioning, in female reproductive system.
The combination of the herbs regulates female hormones and prepares the uterus ideal for reproduction.
The synergistic activity of the combination enhances fertility.
Ingredients of Gynakot Tablet:
Punarnava (Boerhaavia diffusa)- root- 0.750g
Bilva (Aegle marmelos)- root- 0.125g
Patala (Stereospermum colais)- root- 0.125g
Kashmari (Gmelina arborea)- root- 0.125g
Shyonaka (Oroxylum indicum)- root- 0.125g
Agnimantha (Premna corymbosa)- root- 0.125g
Shaliparni (Desmodium gangeticum)- root- 0.125g
Prishniparni (Uraria picta)- root- 0.125g
Brihati (Solanum indicum)- root- 0.250g
Gokshura (Tribulus terrestris)- fruit- 0.125g
Payasya (Holestemmaadakodiyan)- root- 0.125g
Ashwagandha (Withania somnifera)- root- 0.125g
Eranda (Ricinus communis)- root- 0.125g
Satavari (Asperagus racemosus)- root- 0.125g
Darbha (Desmostachya bipinnata)- root- 0.250g
Sara (Saccharum aurundinaceum)- root- 0.125g
Kasa (Saccharum spontaneum)- root- 0.125g
Ikshumula (Saccharum indicum)- root- 0.125g
Potagala (Sphearanthus indicus)- root- 0.125g
Krishna (Piper longum)- fruit- 0.125g
Krishnamula (Piper longum)- root- 0.125g
Yasti (Glycyrrhiza glabra)- root- 0.125g
Mridweeka (Vitis vinifera)- fruit- 0.125g
Jeeraka (Cuminum cyminum)- seed- 0.125g
Nagara (Zingiber officinale)-rhizome- 0.125g
Dosage of Gynakot Tablet:
2 tablets thrice daily, or as directed by the physician
Side effects of Gynakot Tablet:
There are no recorded side effects with this medicine.
Should be taken under medical supervision
Reviews
There are no reviews yet.